[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Ascends But Remains Behind Market: Some Facts to Note",
    "summary": "Eli Lilly (LLY) closed at $827.54 in the latest trading session, marking a +1.16% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=679841ade05387e5faa92b070441cf5e6dbf3fb555103bdfdddb8e59d2d27204",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745358315,
      "headline": "Eli Lilly (LLY) Ascends But Remains Behind Market: Some Facts to Note",
      "id": 134038726,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) closed at $827.54 in the latest trading session, marking a +1.16% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=679841ade05387e5faa92b070441cf5e6dbf3fb555103bdfdddb8e59d2d27204"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill",
    "summary": "Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.",
    "url": "https://finnhub.io/api/news?id=25e70e563857c593b38edcc95b88cc6e0a3476e0c2c49a1f7826394b1e8ffa1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745352363,
      "headline": "Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill",
      "id": 134038727,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.",
      "url": "https://finnhub.io/api/news?id=25e70e563857c593b38edcc95b88cc6e0a3476e0c2c49a1f7826394b1e8ffa1d"
    }
  },
  {
    "ts": null,
    "headline": "Q1 Earnings Season Scorecard and Analyst Reports for NVIDIA, Alphabet & Berkshire Hathaway",
    "summary": "Today's Research Daily features a real-time update on the Q1 earnings season, in addition to updated research reports on 16 major stocks, including NVIDIA (NVDA), Alphabet (GOOGL) and Berkshire Hathaway Inc. (BRK.B).",
    "url": "https://finnhub.io/api/news?id=e63c0b4ac9aaa516bb10dfe28cbb6122f411a7151b342b27701e2060713cc3eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745343720,
      "headline": "Q1 Earnings Season Scorecard and Analyst Reports for NVIDIA, Alphabet & Berkshire Hathaway",
      "id": 134037962,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Today's Research Daily features a real-time update on the Q1 earnings season, in addition to updated research reports on 16 major stocks, including NVIDIA (NVDA), Alphabet (GOOGL) and Berkshire Hathaway Inc. (BRK.B).",
      "url": "https://finnhub.io/api/news?id=e63c0b4ac9aaa516bb10dfe28cbb6122f411a7151b342b27701e2060713cc3eb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom",
    "summary": "President Donald Trump’s tariff policy is the latest blow to a pharmaceutical sector already facing mounting uncertainties, including how Robert F. Kennedy Jr., secretary of Health and Human Services, will change the U.S. healthcare system.  While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector “very shortly.”  A 25% tariff could reduce earnings in the sector by about 15%, Jefferies analyst Akash Tewari noted last week, but mitigation efforts such as stockpiling, increasing drug prices or shifting manufacturing to the U.S. could reduce the damage to the mid single digits.",
    "url": "https://finnhub.io/api/news?id=bb87f87fa47de290d5a66e6b72d3829b49f8e309d26fc95a8a2d94592ea90561",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745334780,
      "headline": "Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom",
      "id": 134038508,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Donald Trump’s tariff policy is the latest blow to a pharmaceutical sector already facing mounting uncertainties, including how Robert F. Kennedy Jr., secretary of Health and Human Services, will change the U.S. healthcare system.  While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector “very shortly.”  A 25% tariff could reduce earnings in the sector by about 15%, Jefferies analyst Akash Tewari noted last week, but mitigation efforts such as stockpiling, increasing drug prices or shifting manufacturing to the U.S. could reduce the damage to the mid single digits.",
      "url": "https://finnhub.io/api/news?id=bb87f87fa47de290d5a66e6b72d3829b49f8e309d26fc95a8a2d94592ea90561"
    }
  },
  {
    "ts": null,
    "headline": "3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold",
    "summary": "When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.  Three Fool.com contributors believe they've identified relatively safe growth stocks in the healthcare sector that you can buy and hold.  Here's why they picked Amgen (NASDAQ: AMGN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX).",
    "url": "https://finnhub.io/api/news?id=53c5b17920fda4f31948747fce1f9dbe0959aeee07b477b2a769b41bc9954da4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745329980,
      "headline": "3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold",
      "id": 134038730,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.  Three Fool.com contributors believe they've identified relatively safe growth stocks in the healthcare sector that you can buy and hold.  Here's why they picked Amgen (NASDAQ: AMGN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX).",
      "url": "https://finnhub.io/api/news?id=53c5b17920fda4f31948747fce1f9dbe0959aeee07b477b2a769b41bc9954da4"
    }
  },
  {
    "ts": null,
    "headline": "Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy",
    "summary": "Investing.com -- Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth visibility and limited exposure to policy headwinds.",
    "url": "https://finnhub.io/api/news?id=fb797e9d859b02cce2cfd30df698c57a5a3a2d8623dade1fe4a1f6047414ee40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745329681,
      "headline": "Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy",
      "id": 134038510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth visibility and limited exposure to policy headwinds.",
      "url": "https://finnhub.io/api/news?id=fb797e9d859b02cce2cfd30df698c57a5a3a2d8623dade1fe4a1f6047414ee40"
    }
  },
  {
    "ts": null,
    "headline": "Best Leveraged ETFs of Last Week",
    "summary": "Wall Street delivered mixed-to-downbeat performance last week thanks to Powell's warning of stagflation, rise of auto stocks on policy hopes, NVIDIA's $5.5B hit on export curb and upbeat retail sales.",
    "url": "https://finnhub.io/api/news?id=ffa237dd5cf36afa34cec09b1c03f4d595a84d335788d4669501a198c0100b0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745323620,
      "headline": "Best Leveraged ETFs of Last Week",
      "id": 134038732,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Wall Street delivered mixed-to-downbeat performance last week thanks to Powell's warning of stagflation, rise of auto stocks on policy hopes, NVIDIA's $5.5B hit on export curb and upbeat retail sales.",
      "url": "https://finnhub.io/api/news?id=ffa237dd5cf36afa34cec09b1c03f4d595a84d335788d4669501a198c0100b0f"
    }
  },
  {
    "ts": null,
    "headline": "Cantor Fitzgerald Initiates Coverage of Eli Lilly and (LLY) with Overweight Recommendation",
    "summary": "Cantor Fitzgerald Initiates Coverage of Eli Lilly and (LLY) with Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=4749b310113d070e5953cdcd37d57776628048cb156a643f7726c2537ad57a16",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745323482,
      "headline": "Cantor Fitzgerald Initiates Coverage of Eli Lilly and (LLY) with Overweight Recommendation",
      "id": 134032752,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4749b310113d070e5953cdcd37d57776628048cb156a643f7726c2537ad57a16"
    }
  },
  {
    "ts": null,
    "headline": "These companies have announced their intention to increase US manufacturing",
    "summary": "Numerous companies have unveiled investments in U.S. manufacturing in recent weeks, including TSMC, Eli Lilly, Hyundai Motor Group and others.",
    "url": "https://finnhub.io/api/news?id=ff66a5a6a6e88534da67cffced382a5bd0b75167ed7910269deaf4fb89445b49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745319641,
      "headline": "These companies have announced their intention to increase US manufacturing",
      "id": 134038733,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Numerous companies have unveiled investments in U.S. manufacturing in recent weeks, including TSMC, Eli Lilly, Hyundai Motor Group and others.",
      "url": "https://finnhub.io/api/news?id=ff66a5a6a6e88534da67cffced382a5bd0b75167ed7910269deaf4fb89445b49"
    }
  },
  {
    "ts": null,
    "headline": "US Stock Future Bounce and Gold Tops Record $3,500: Markets Wrap",
    "summary": "(Bloomberg) -- US stocks are set to bounce back from Monday’s losses as investors nervously weighed up progress on trade talks with India and Tesla Inc.’s upcoming earnings. Gold topped $3,500 for the first time.Most Read from BloombergDOGE Visits National Gallery of Art to Discuss Museum’s Legal StatusTrump Gives New York ‘One Last Chance’ to End Congestion FeeTrump Administration Takes Over New York Penn Station RevampThe Racial Wealth Gap Is Not Just About MoneyNashville’s $3 Billion Transit",
    "url": "https://finnhub.io/api/news?id=9b60c9937b9a92a5c2761cbb2c2f20e1b02e15d28d71555e650dfd4a24f8d9bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745319316,
      "headline": "US Stock Future Bounce and Gold Tops Record $3,500: Markets Wrap",
      "id": 134031873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- US stocks are set to bounce back from Monday’s losses as investors nervously weighed up progress on trade talks with India and Tesla Inc.’s upcoming earnings. Gold topped $3,500 for the first time.Most Read from BloombergDOGE Visits National Gallery of Art to Discuss Museum’s Legal StatusTrump Gives New York ‘One Last Chance’ to End Congestion FeeTrump Administration Takes Over New York Penn Station RevampThe Racial Wealth Gap Is Not Just About MoneyNashville’s $3 Billion Transit",
      "url": "https://finnhub.io/api/news?id=9b60c9937b9a92a5c2761cbb2c2f20e1b02e15d28d71555e650dfd4a24f8d9bc"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Shares Fall After Data From New Eli Lilly Pill",
    "summary": "Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s blockbuster shots.",
    "url": "https://finnhub.io/api/news?id=679c77fa3aca1e4a0281c3e1c2fc0ab05b3206c5e5ad640e6b5d5b34fa092f27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745313780,
      "headline": "Novo Nordisk Shares Fall After Data From New Eli Lilly Pill",
      "id": 134031890,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s blockbuster shots.",
      "url": "https://finnhub.io/api/news?id=679c77fa3aca1e4a0281c3e1c2fc0ab05b3206c5e5ad640e6b5d5b34fa092f27"
    }
  },
  {
    "ts": null,
    "headline": "Novo shares down on Eli Lilly’s positive obesity pill data",
    "summary": "Investing.com -- Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and blood sugar control comparable to injectable treatments like Ozempic.",
    "url": "https://finnhub.io/api/news?id=12a2903aee1abc5b30e13f7dfc6b0744ff18246f16c345acf4be49080918ea90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745310841,
      "headline": "Novo shares down on Eli Lilly’s positive obesity pill data",
      "id": 134031146,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and blood sugar control comparable to injectable treatments like Ozempic.",
      "url": "https://finnhub.io/api/news?id=12a2903aee1abc5b30e13f7dfc6b0744ff18246f16c345acf4be49080918ea90"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Drops on Weight-Loss Study by Rival Lilly",
    "summary": "Novo Nordisk slumped after a pill from rival Eli Lilly helped patients shed weight and control blood sugar about as well as its injected blockbuster Ozempic. Bloomberg Intelligence's Sam Fazeli explains.",
    "url": "https://finnhub.io/api/news?id=f5fbf25ff062a8d732bdf973fc26ba3cd08c290985c3013e9da0b5408df957e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745308208,
      "headline": "Novo Nordisk Drops on Weight-Loss Study by Rival Lilly",
      "id": 134031147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk slumped after a pill from rival Eli Lilly helped patients shed weight and control blood sugar about as well as its injected blockbuster Ozempic. Bloomberg Intelligence's Sam Fazeli explains.",
      "url": "https://finnhub.io/api/news?id=f5fbf25ff062a8d732bdf973fc26ba3cd08c290985c3013e9da0b5408df957e4"
    }
  }
]